Clinical Trials Logo

Glaucoma, Open-Angle clinical trials

View clinical trials related to Glaucoma, Open-Angle.

Filter by:

NCT ID: NCT02754596 Completed - Glaucoma Open-angle Clinical Trials

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

Start date: March 29, 2016
Phase: Phase 2
Study type: Interventional

This is a randomized trial comparing two elution doses of the Travoprost Intraocular implant to timolol ophthalmic solution.

NCT ID: NCT02754570 Completed - Clinical trials for Glaucoma, Open-angle

The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure

Start date: July 2016
Phase: N/A
Study type: Interventional

The aim of this study will be to determine the effects of pilocarpine as an adjunct medication to latanoprost monotherapy at multiple intervals throughout a 24-hour period and compare these effects to latanoprost alone.

NCT ID: NCT02743780 Completed - Ocular Hypertension Clinical Trials

A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma

Start date: March 2, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).

NCT ID: NCT02742649 Completed - Ocular Hypertension Clinical Trials

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension

Start date: April 30, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if a combination of two drugs (bimatoprost and timolol) delivered to the surface of the eye over 10 weeks is better at lowering intraocular pressure (IOP) than either of the drugs delivered alone.

NCT ID: NCT02730871 Terminated - Ocular Hypertension Clinical Trials

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

Start date: June 24, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension.

NCT ID: NCT02713152 Completed - Open Angle Glaucoma Clinical Trials

Prevalence of Obstructive Sleep Apnoea in Glaucoma

POSAG
Start date: March 2016
Phase: N/A
Study type: Observational

This study aims to investigate a potential link between Obstructive Sleep Apnoea (OSA) and Open Angle Glaucoma (OAG); initially by determining whether the prevalence of OSA is higher in patients with OAG in comparison to people without glaucoma and if OSA is an independent risk factor for OAG. It will comprehensively phenotype glaucoma patients for variables that may be associated with both OSA and OAG.

NCT ID: NCT02700984 Completed - Clinical trials for Primary Open Angle Glaucoma (POAG)

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

COMPASS-XT
Start date: March 30, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of the CyPass Micro-Stent in subjects who completed Study Protocol TMI-09-01, COMPASS Trial.

NCT ID: NCT02679482 Recruiting - Clinical trials for Glaucoma, Open-Angle

Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma

FPSPLTTCOAG
Start date: September 2014
Phase: N/A
Study type: Observational

The purpose of this study is to follow and describe the outcomes of patients after selective and pascal laser trabeculoplasty treatment for chronic open-angle glaucoma.

NCT ID: NCT02674854 Completed - Ocular Hypertension Clinical Trials

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Start date: February 2016
Phase: Phase 3
Study type: Interventional

To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%

NCT ID: NCT02638181 Completed - Open-angle Glaucoma Clinical Trials

The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork

Start date: July 2013
Phase: N/A
Study type: Interventional

This study was to assess the distinct expression of matrix metalloproteinase 13,tissue inhibitor of metalloproteinases 3, and calcium-sensing receptor, in human trabecular meshwork between normal and glaucomatous eyes.The expressions of matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3 and calcium-sensing receptor in the trabecular meshwork tissues were examined by streptavidin-peroxidase immunohistochemical staining method and western blot, and histological changes of trabecular meshwork were studied by Hematoxylin and Eosin staining.